Introduction
Non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations, particularly exon 19 deletions and L858R substitutions, comprises a significant subset of lung cancers. The advent of EGFR tyrosine kinase inhibitors (TKIs), especially osimertinib, has markedly improved prognosis. However, most patients eventually develop resistance, often through additional mutations or bypass mechanisms, leading to disease progression. Standard treatment options after progression on osimertinib and platinum-based chemotherapy are limited, necessitating novel therapeutic strategies.
The recent study from the CHRYSALIS-2 cohort A investigates the efficacy and safety of combining amivantamab, an EGFR-MET bispecific antibody, with lazertinib, a third-generation EGFR TKI, in this heavily pretreated patient population. This study aims to address the unmet clinical need for effective salvage therapies in EGFR-mutant NSCLC following resistance to prior targeted therapy and chemotherapy.
